

C 1 ^{sub} Df
c) a biologically-active fragment of the amino acid sequence of SEQ ID NO:1, and
d) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:1.

C 2
11. (Once Amended.) A purified antibody which binds specifically to [the] a polypeptide of claim 1.

12. (Once Amended.) A purified agonist which specifically binds to and modulates the activity of [the] a polypeptide of claim 1.

13. (Once Amended.) A purified antagonist which specifically binds to and modulates the activity of [the] a polypeptide of claim 1.

14. (Reiterated.) A pharmaceutical composition comprising a substantially purified antagonist of claim 13 in conjunction with a suitable pharmaceutical carrier.

15. (Reiterated.) A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 14.

16. (Reiterated.) A method for treating disorders of the prostate comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 14.

Please add the following new claims:

C 3 ^{sub} 26
18. (New) A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1.

19. (New) A pharmaceutical composition comprising a polypeptide of claim 18 in conjunction with a suitable pharmaceutical carrier.

20. (New) A pharmaceutical composition comprising a polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

21. (New) An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide sequence of SEQ ID NO:2,
b) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2 and
b) a polynucleotide sequence complementary to a) or b).

22. (New) A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 21, comprising
hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and
detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

23. (New) A method of claim 22, wherein the probe comprises at least 30 contiguous nucleotides.

24. (New) A method of claim 22, wherein the probe comprises at least 60 contiguous nucleotides.